ArticleAddictive behaviors2026
Medication for opioid use disorder among adolescents entering specialty treatment for opioid use disorder and trends in the US, 2017-2022.
Article in Addictive behaviors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundProfessional societies recommend that adolescents with opioid use disorder (OUD) receive medication for opioid use disorder (MOUD). This cross-sectional study examined the association between adolescent specialty treatment episodes for OUD with planned MOUD use compared to adults over time.
methodsWe used data on first episodes of specialty treatment for OUD (n = 671,183) from the Treatment Episode Data Set - Admissions, a national database of publicly funded treatment programs in the US Admissions occurred between 1/2017-12/2022. The primary exposure was being adolescent (15-17 years). The main outcome was planned MOUD use, defined as having MOUD in a treatment plan.
resultsAdolescent specialty treatment episodes for OUD were significantly less likely to have planned MOUD use than adults (aOR 0.05, 95% CI, 0.02-0.09). Linear combination tests of the interaction between age group and year confirmed that adolescent episodes were significantly less likely to have planned MOUD use than adults across all years. In 2021 and 2022 this disparity narrowed slightly. In 2021, adolescent episodes had 10% of the adjusted odds of planned MOUD use compared to adults in 2017 (95% CI, 0.07-0.15). In 2022, adolescent episodes had 9% of the adjusted odds of planned MOUD use compared to adults in 2017 (95% CI, 0.06-0.11).
conclusionAdolescents entering specialty treatment for OUD had significantly lower odds of planned MOUD use than adults. The relatively smaller difference between adolescents and adults in recent years suggests a potential trend toward greater MOUD access, though future research is needed to understand access barriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.